Examination of the sensitivity, specificity, accuracy and MCC for a set of BRCA1 and BRCA2 mutations alone sheds little light on the amounts of patients that would be affected by misleading findings in a clinical setting, e.g., genetic testing in families at risk for breast and ovarian cancer. This evidence concerns the gene BRCA1 and ovarian cancer.